Journal
JOURNAL OF THORACIC DISEASE
Volume 11, Issue -, Pages S45-S56Publisher
AME PUBL CO
DOI: 10.21037/jtd.2018.12.80
Keywords
Circulating tumor cells (CTC); non-small cell lung cancer (NSCLC); liquid biopsy
Categories
Funding
- Fondation pour la Recherche Medicale [FDT20160435543, FDT20150532072]
- Fondation de France [201300038317]
- Fondation ARC pour la Recherche sur le Cancer [20131200417]
- Innovative Medicines Initiative 11th Call CANCER ID [IMI-JU-11-2013, 115749]
- Institut National du Cancer [PRT-K14-032]
- Agence Nationale de la Recherche [ANR-CE17-0006-01]
Ask authors/readers for more resources
Growing evidences for tumor heterogeneity confirm that single-tumor biopsies frequently fail to reveal the widespread mutagenic profile of tumor. Repeated biopsies are in most cases unfeasible, especially in advanced cancers. We describe here how circulating tumor cells (CTCs) isolated from minimally invasive blood sample might inform us about intratumor heterogeneity, tumor evolution and treatment resistance. We also discuss the advances of CTCs research, most notably in molecularly selected non-small cell lung cancer (NSCLC) patients, highlighting challenges and opportunities related to personalized therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available